Small Pharmaceuticals
Market Cap
₹18,531 ₹18,531 Cr.
P/E
0.00
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

Base case activates as GLP-1 commercialization scales DDC cartridge utilization from ~30% to 70%+, biologics begins commercial production by FY29, and no major compliance disruption interrupts the ramp

Bull case requires US semaglutide acceleration post-patent and the paused Steriscience acquisition closing in FY28, which together would add ~$100m revenue and unlock a valuation re-rating toward premier CDMO multiples

Bear case is driven by further customer approval delays exceeding six months, oral GLP-1 stealing >25% of anti-obesity market share, and biologics funnel conversion remaining too low to offset pressure on the GLP-1 injectables franchise

  • Onesource Specialty
  • Eris Lifesciences
  • Caplin Point Labs.

FAQs on Onesource Specialty Pharma Ltd. Shareprice

Onesource Specialty has given lower returns compared to its competitors.
Onesource Specialty has grown at ~-14.17% over the last 1yrs while peers have grown at a median rate of 12.36%

Onesource Specialty is not expensive.
Latest PE of Onesource Specialty is 191, while 3 year average PE is 333.
Also latest EV/EBITDA of Onesource Specialty is 50.4 while 3yr average is 72.77.

Growth Table

  • Onesource Specialty Pharma Ltd.
  • Eris Lifesciences
  • Caplin Point Labs.

Balance Sheet

  • Onesource Specialty Pharma Ltd.
  • Eris Lifesciences
  • Caplin Point Labs.

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Onesource Specialty Pharma Ltd.
  • Eris Lifesciences
  • Caplin Point Labs.

Cash Flow

  • Onesource Specialty Pharma Ltd.
  • Eris Lifesciences
  • Caplin Point Labs.

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Onesource Specialty Pharma Ltd.
  • Eris Lifesciences
  • Caplin Point Labs.

Quarterly Results

  • Onesource Specialty Pharma Ltd.
  • Eris Lifesciences
  • Caplin Point Labs.

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Onesource Specialty Pharma Ltd. Financials

Balance sheet of Onesource Specialty is strong.
But short term working capital might become an issue for this company.

Yes, The net debt of Onesource Specialty is increasing.
Latest net debt of Onesource Specialty is ₹1,451 Crs as of Sep-26.
This is greater than Mar-26 when it was ₹1,081 Crs.

The profit is oscillating.
The profit of Onesource Specialty is -₹1.62 Crs for TTM, -₹73.8 Crs for Mar 2026 and -₹17.97 Crs for Mar 2025.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Onesource Specialty latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Inventory, Accounts Receivable

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech